CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- 4 Planned sale Chief Development Officer sold 29,709 shares at an average $29.69 ($881,915)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure · Other events
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SC 13G Stake Amended Statement of Ownership
- 4 Option exercise Chief Financial Officer acquired 70,000 shares (option exercise)
- 4 Open-market sale Chief Scientific Officer sold 75,000 shares at an average $28.27 ($2,120,101)
- 4 Open-market sale General Counsel sold 70,922 shares at an average $28.15 ($1,996,574)
- 4 Open-market sale CMO sold 7,162 shares at $28.29 ($202,603)
- 4 Open-market sale Chief Business Officer sold 42,068 shares at $29.03 ($1,221,133)
- 4 Open-market sale Chief Financial Officer sold 125,092 shares at an average $28.57 ($3,573,980)
Page 8 of 22 · 423 filings